Fundraising Fox

Sonalasense

Berkeley, US · Founded 2019 · New York corporation · 1 known investors

SonALAsense develops Sonodynamic Therapy (SDT), a non-invasive drug-device cancer treatment combining its SONALA-001 drug with an ultrasound device to treat deadly cancers such as High-Grade Gliomas and DIPG. The company is running Phase 0/1 and Phase 1/2 clinical trials and targets patients with brain tumors that typically require surgery.

BiotechHealthtechMedical Devices

Founders & leadership

SM
Stuart MarcusNamed on SEC filing
MP
Mark P. de SouzaNamed on SEC filing

Investors · 1

Keiretsu ForumSan Francisco · $250K – $2M

Reported raises · per SEC filings

Form D private placements

$34.8M disclosed across 4 rounds · 2019–2023

▶$9.8MraisedNov 2023 · 30 investors · Biotechnology
Rule 506(b)
Officers, directors & promoters on the filing
  • MARK P. DE SOUZAExecutive Officer, Director
  • STUART MARCUSExecutive Officer, Director
  • VINCENT SAIDirector
Offering amount
$15M
Amount sold
$9.8M
First sale
Feb 2023
Incorporated
Corporation, New York, 2019
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$20.1MraisedJan 2022 · 30 investors · Biotechnology
Rule 506(b)
Officers, directors & promoters on the filing
  • Stuart MarcusExecutive Officer, Director
  • Mark P. de SouzaExecutive Officer, Director
Offering amount
$30.1M
Amount sold
$20.1M
First sale
Dec 2021
Incorporated
Corporation, Delaware, 2019
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$3.9MraisedFeb 2021 · 26 investors · Biotechnology
Rule 506(b)
Officers, directors & promoters on the filing
  • Stuart MarcusExecutive Officer, Director
  • Mark P. de SouzaExecutive Officer, Director
Offering amount
$8M
Amount sold
$3.9M
First sale
Feb 2021
Incorporated
Corporation, Delaware, 2019
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$1000KraisedSep 2020 · 13 investors · Biotechnology
Rule 506(b)
Officers, directors & promoters on the filing
  • Stuart MarcusExecutive Officer, Director
  • Mark P. de SouzaExecutive Officer, Director
Offering amount
$2M
Amount sold
$1000K
First sale
Dec 2019
Incorporated
Corporation, Delaware, 2019
Federal exemptions
06b
Full filing on SEC EDGAR ↗

Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.

Competitors · 1

by search overlap
HistoSonics4 shared keywordsHistoSonics develops histotripsy technology, a non-invasive method that uses focused sound energy to destroy targeted tissue, offered as a medical device for physicians and their patients. The company markets its technology to healthcare providers internationally.

Companies competing with Sonalasense for the same Google search keywords, organic and paid, via search-intersection analysis.

Non-dilutive funding · 2 SBIR/STTR awards

Federal grants — no equity taken
AgencyPhaseYearAmount
National Institutes of Health (NIH)National Institutes of HealthPhase II2023$694.8K
National Institutes of Health (NIH)National Institutes of HealthPhase II2022$2M

Source: SBIR.gov award data (U.S. Small Business Administration). SBIR/STTR awards are competitive federal R&D grants and contracts — non-dilutive capital alongside any venture rounds above.

Frequently asked questions

What does Sonalasense do?
SonALAsense develops Sonodynamic Therapy (SDT), a non-invasive drug-device cancer treatment combining its SONALA-001 drug with an ultrasound device to treat deadly cancers such as High-Grade Gliomas and DIPG. The company is running Phase 0/1 and Phase 1/2 clinical trials and targets patients with brain tumors that typically require surgery.
Who are Sonalasense's investors?
Sonalasense's investors include Keiretsu Forum.
How much funding has Sonalasense raised?
Sonalasense has disclosed $34.8M raised across 4 rounds.
Where is Sonalasense headquartered?
Sonalasense is headquartered in Berkeley, US.